IBDEI2MK ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4,2050,0)
 ;;=PROSTATIC CONDITIONS^10^162
 ;;^UTILITY(U,$J,358.4,2051,0)
 ;;=TESTICULAR CONDITIONS^12^162
 ;;^UTILITY(U,$J,358.4,2052,0)
 ;;=URETHRAL CONDITIONS^13^162
 ;;^UTILITY(U,$J,358.4,2053,0)
 ;;=URINARY SYMPTOMS^14^162
 ;;^UTILITY(U,$J,358.4,2054,0)
 ;;=CEREBROVASCULAR ARTERIAL STUDIES^1^163
 ;;^UTILITY(U,$J,358.4,2055,0)
 ;;=EXTREMITY ARTERIAL-VENOUS STUDIES^3^163
 ;;^UTILITY(U,$J,358.4,2056,0)
 ;;=EXTREMITY VENOUS STUDIES^4^163
 ;;^UTILITY(U,$J,358.4,2057,0)
 ;;=VISCERAL/PENILE VASCULAR STUDIES^6^163
 ;;^UTILITY(U,$J,358.4,2058,0)
 ;;=EXTREMITY ARTERIAL STUDIES^2^163
 ;;^UTILITY(U,$J,358.4,2059,0)
 ;;=ULTRASOUNDS^5^163
 ;;^UTILITY(U,$J,358.4,2060,0)
 ;;=COMMON VASCULAR DX^1^164
 ;;^UTILITY(U,$J,358.4,2061,0)
 ;;=ABDOMINAL PAIN^2^164
 ;;^UTILITY(U,$J,358.4,2062,0)
 ;;=AFTERCARE POST SURGERY^3^164
 ;;^UTILITY(U,$J,358.4,2063,0)
 ;;=CARDIOVASCULAR^4^164
 ;;^UTILITY(U,$J,358.4,2064,0)
 ;;=METASTATIC CANCER SITES^5^164
 ;;^UTILITY(U,$J,358.4,2065,0)
 ;;=POST-OP COMPLICATIONS^6^164
 ;;^UTILITY(U,$J,358.4,2066,0)
 ;;=RESPIRATORY^8^164
 ;;^UTILITY(U,$J,358.4,2067,0)
 ;;=SIGNS & SYMPTOMS^9^164
 ;;^UTILITY(U,$J,358.4,2068,0)
 ;;=PRE-OP^7^164
 ;;^UTILITY(U,$J,358.4,2069,0)
 ;;=NEW PATIENT^2^165
 ;;^UTILITY(U,$J,358.4,2070,0)
 ;;=ESTABLISHED PATIENT^1^165
 ;;^UTILITY(U,$J,358.4,2071,0)
 ;;=CONSULTATIONS^3^165
 ;;^UTILITY(U,$J,358.4,2072,0)
 ;;=DEBRIDEMENT^1^166
 ;;^UTILITY(U,$J,358.4,2073,0)
 ;;=I&D/ASPIRATION^2^166
 ;;^UTILITY(U,$J,358.4,2074,0)
 ;;=UNNA BOOT^4^166
 ;;^UTILITY(U,$J,358.4,2075,0)
 ;;=PEG TUBE^3^166
 ;;^UTILITY(U,$J,358.4,2076,0)
 ;;=WOUND VAC DRESSING^6^166
 ;;^UTILITY(U,$J,358.4,2077,0)
 ;;=VASCULAR PROCEDURES^5^166
 ;;^UTILITY(U,$J,358.4,2078,0)
 ;;=COMMON VASCULAR DX^1^167
 ;;^UTILITY(U,$J,358.4,2079,0)
 ;;=ABDOMINAL PAIN^2^167
 ;;^UTILITY(U,$J,358.4,2080,0)
 ;;=AFTERCARE POST SURGERY^3^167
 ;;^UTILITY(U,$J,358.4,2081,0)
 ;;=CARDIOVASCULAR^4^167
 ;;^UTILITY(U,$J,358.4,2082,0)
 ;;=METASTATIC CANCER SITES^5^167
 ;;^UTILITY(U,$J,358.4,2083,0)
 ;;=POST-OP COMPLICATIONS^6^167
 ;;^UTILITY(U,$J,358.4,2084,0)
 ;;=RESPIRATORY^8^167
 ;;^UTILITY(U,$J,358.4,2085,0)
 ;;=SIGNS & SYMPTOMS^9^167
 ;;^UTILITY(U,$J,358.4,2086,0)
 ;;=PRE-OP^7^167
 ;;^UTILITY(U,$J,358.4,2087,0)
 ;;=NEW PATIENT^2^168
 ;;^UTILITY(U,$J,358.4,2088,0)
 ;;=ESTABLISHED PATIENT^1^168
 ;;^UTILITY(U,$J,358.4,2089,0)
 ;;=CONSULTATIONS^3^168
 ;;^UTILITY(U,$J,358.4,2090,0)
 ;;=POST-OP F/U VISIT^5^168
 ;;^UTILITY(U,$J,358.4,2091,0)
 ;;=GYN PROCEDURES^1^169
 ;;^UTILITY(U,$J,358.4,2092,0)
 ;;=INJECTIONS^11^169
 ;;^UTILITY(U,$J,358.4,2093,0)
 ;;=INJECTION ADMINISTRATION^10^169
 ;;^UTILITY(U,$J,358.4,2094,0)
 ;;=EAR WAX REMOVAL^5^169
 ;;^UTILITY(U,$J,358.4,2095,0)
 ;;=CARDIAC^2^169
 ;;^UTILITY(U,$J,358.4,2096,0)
 ;;=FOREIGN BODY^8^169
 ;;^UTILITY(U,$J,358.4,2097,0)
 ;;=UA/FINGERSTICK^15^169
 ;;^UTILITY(U,$J,358.4,2098,0)
 ;;=FLUSHES^6^169
 ;;^UTILITY(U,$J,358.4,2099,0)
 ;;=TB TEST^14^169
 ;;^UTILITY(U,$J,358.4,2100,0)
 ;;=DRAIN/INJECT JOINT^4^169
 ;;^UTILITY(U,$J,358.4,2101,0)
 ;;=DESTRUCTION OF LESIONS^3^169
 ;;^UTILITY(U,$J,358.4,2102,0)
 ;;=IMMUNIZATIONS^9^169
 ;;^UTILITY(U,$J,358.4,2103,0)
 ;;=IMMUNIZATION ADMINISTRATION^8^169
 ;;^UTILITY(U,$J,358.4,2104,0)
 ;;=PREVENTIVE MED-EST PT^12^169
 ;;^UTILITY(U,$J,358.4,2105,0)
 ;;=PREVENTIVE MED-NEW PT^13^169
 ;;^UTILITY(U,$J,358.4,2106,0)
 ;;=GENITOURINARY & RENAL^5^170
 ;;^UTILITY(U,$J,358.4,2107,0)
 ;;=GYNECOLOGICAL/BREAST^6^170
 ;;^UTILITY(U,$J,358.4,2108,0)
 ;;=CARDIO/VASCULAR^1^170
 ;;^UTILITY(U,$J,358.4,2109,0)
 ;;=ENDOCRINE/METABOLIC/NUTRITION^2^170
 ;;^UTILITY(U,$J,358.4,2110,0)
 ;;=EYES/EARS/NOSE^3^170
